Related coverage linked through entity extraction aliases.
Apr 11, 2026
Two phase 3 trials found upadacitinib 15 mg significantly improved facial and total repigmentation versus placebo at 48 weeks in nonsegmental vitiligo. The 614-patient studies also showed continued improvement over time and a safety profile consistent with prior use.
Apr 10, 2026
A study identified host-response plasma protein candidate biomarkers to predict venous thromboembolism risk after pleural mesothelioma surgery. The exploratory cohort included 18 patients.
Apr 04, 2026
A clinical study in Shock found that Nu.Q H3.1 and H3R8 Citrulline were significantly elevated in 674 trauma patients, especially those who developed VTE. The findings point to potential clinical utility for trauma care and support commercialization of Nu.Q NETs.
Mar 28, 2026
CRISPR Therapeutics reported a Q4 2025 loss of $1.37 per share, missing estimates, with revenues of $0.9 million falling short of expectations. The company's partner Vertex recorded $54 million in Casgevy sales for the quarter, with regulatory submissions for pediatric label expansion planned for early 2026.
Feb 21, 2026
The FDA has approved a once-monthly dosing schedule for subcutaneous amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) combined with lazertinib for first-line treatment of EGFR-mutated advanced NSCLC, based on PALOMA-2 trial data showing comparable efficacy to biweekly dosing.
Dec 18, 2025
The FDA approved a once-monthly dosing schedule for Rybrevant Faspro with Lazcluze for first-line treatment of EGFR-mutated advanced NSCLC, reducing clinic visits while maintaining safety and efficacy established with bi-weekly dosing.
